請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/7984
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 李財坤(Tsai-Kun Li) | |
dc.contributor.author | Wei-Jen Chen | en |
dc.contributor.author | 陳薇任 | zh_TW |
dc.date.accessioned | 2021-05-19T18:01:27Z | - |
dc.date.available | 2021-08-20 | |
dc.date.available | 2021-05-19T18:01:27Z | - |
dc.date.copyright | 2019-08-20 | |
dc.date.issued | 2019 | |
dc.date.submitted | 2019-08-17 | |
dc.identifier.citation | 參考文獻
1. 王道還,(2014),微生物的抗藥性,500期,P. 76 ~ 79,科學發展。 2. 陳彥旭,(2018),抗生素的發明、演進與困境,科技大觀園,網址: https://scitechvista.nat.gov.tw/c/sTNc.htm。 3. Centers for Disease Control and Prevention (CDC), INFORMS, Stable URL: https://www.cdc.gov/. 4. 何邦立,(1983),抗生素,中華百科全書,網址: http://ap6.pccu.edu.tw/Encyclopedia_media/main-usesc.asp?id=2767。 5. 王修含,(2013),抗生素(antibiotics)的藥理學機轉,網址:http://www.skin168.net/2013/12/antibiotics.html。 6. 張家銘,陳立佳,柯文謙,(1999),乙內醯胺類抗生素及其抗藥性,P. 185-197,內科學誌。 7. (2018), Antimicrobial resistance, WHO, INFORMS, Stable URL: http://www.who.int/mediacentre/factsheets/fs194/en/. 8. Bouchardeau Cecile, Schlesinger Richard, (2001), Antibiotic kill or cure? , CBS News Productions, Discovery Health Channel. 9. Emily Leung , Diana E Weil , Mario Raviglione , Hiroki Nakatani, (2011), The WHO policy package to combat antimicrobial resistance, Interfaces, Vol. 89, No. 5, P. 390-392, WHO, INFORMS, Stable URL: https://www.who.int/bulletin/volumes/89/5/11-088435/en/. 10. 張筱玲,吳宣建,許甄晏,胡育昇,徐啟勝,林恩惠,(2017),導入醫療機構建構抗生素抗藥性自動通報系統研究計畫,計畫編號:MOHW106-CDC-C-315-114801,衛生福利部疾病管制署 106年署內科技研究計畫,網址: https://www.cdc.gov.tw/uploads/files/46cc487b-9db1-46cc-8002-5f4713d4474f.pdf。 11. (2011), Infectious Diseases Society of America, IDSA, INFORMS, Stable URL: https://www.idsociety.org/clinical-practice/antimicrobial-stewardship/. 12. O’Neill J, (2014), Antimicrobial Resistance: Tackling a Crisis for the Future Health and Wealth of Nations, INFORMS, Stable URL: http://amr-review.org/home . 13. (2013), Global Risks Report, World Economic Forum, INFORMS, Stable URL: http://www.weforum.org/reports/global-risks-2013-eighthedition . 14. (2017), Surveillance of antimicrobial resistance in Europe, European Centre for Disease Prevention and Control (ECDC), INFORMS, Stable URL: https://ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2017 . 15. (2014), The global economic impact of anti-microbial resistance KPMG LLP, INFORMS, Stable URL: http://www.kpmg.co.uk . 16. 楊麗萍,(2018),死亡人數將超癌症!專家預計:2050年1000萬人將死於抗生素濫用,網址:https://kknews.cc/world/pgb3ez8.html。 17. Atsuko Tsutsui, Koji Yahara, Keigo Shibayama, (2018), Trends and patterns of national antimicrobial consumption in Japan from 2004 to 2016, Interfaces, Vol. 24, No. 6, P. 414–421, Journal of Infection and Chemotherapy, Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Higashimurayama, Tokyo 189-0002, Japan, INFORMS, Stable URL: https://www.jiac-j.com/article/S1341-321X(18)30008-4/fulltext?mobileUi=0. 18. (2019),臺灣抗生素抗藥性管理通報系統簡介,第35卷第3期,疫情報導。 19. 周偉惠,曾淑慧,柯玉芬,(2015),台灣抗生素抗藥性管理政策與國家型抗生素管理計畫,第25卷第3期,衛生福利部疾病管制署。 20. (2018),台灣106年平均壽命,內政部統計處。 21. Eili Y. Klein, Thomas P. Van Boeckel, Elena M. Martinez, Suraj Pant, Sumanth Gandra, Simon A. Levin, Herman Goossens, Ramanan Laxminarayan, (2018), Global increase and geographic convergence in antibiotic consumption between 2000 and 2015, Interfaces, Vol. 115, No.15, P. 3463-3470, INFORMS, Stable URL: https://doi.org/10.1073/pnas.1717295115. 22. 張上淳,(2015),抗生素管理手冊National Action Plan Antimicrobial Stewardship Program,衛生福利部。 23. Falagas ME, Kasiakou SK, (2005), Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections, Interfaces, Vol. 40, No.9, P.1333-41, INFORMS, Stable URL: https://www.ncbi.nlm.nih.gov/pubmed/15825037. 24. (2018),2017年國民醫療保健支出指標,衛生福利部、行政院主計總處、內政部,網址: https://dep.mohw.gov.tw/DOS/cp-2156-45963-113.html。 25. (2018),中國抗菌藥物管理和細菌抗藥現狀報告,網址: http://www.nhc.gov.cn/yzygj/s3594/201904/1b5a42f0e326487295b260c813da9b0e/files/c4328389c1b2462983fa94da9093cd05.pdf。 26. (2018),台灣院內感染監測資訊系統(TNIS),2017年第4季監視報告,衛生福利部疾病管制署。 27. (2019), The Global Use of Medicine in 2019 and Outlook to 2023 Forecasts and Areas to Watch Institute Report, IQVIA, INFORMS, Stable URL: https://www.iqvia.com/institute/reports/the-global-use-of-medicine-in-2019-and-outlook-to-2023. 28. (2018), Announces April Price Changes for Devices and Drugs, Pacific Bridge Medical, Japan, INFORMS, Stable URL: https://www.pacificbridgemedical.com/news-brief/japan-announces-april-price-changes-devices-drugs/. 29. (2018),經濟部2018生技產業白皮書,P. 16、27、28,經濟部生技醫藥產業發展推動小組,網址:https://old.www.biopharm.org.tw/white_book.php?li=1. 30. 江望月,(2018),前瞻產業研究院,2018年抗生素類化學原料藥市場現狀及發展趨勢分析產量持續下滑,網址:https://www.qianzhan.com/analyst/detail/220/181227-749ae925.html. 31. (2019), Antibiotics Market - Growth, Trends, and Forecast (2019 - 2024), Research and Markets, INFORMS, Stable URL: https://www.researchandmarkets.com/research/3rl2rm/world_antibiotics?w=4. 32. (2019), Antibiotics Market Size, Share & Trends Analysis Report By Action Mechanism (Protein, DNA, RNA, Cell Wall Synthesis Inhibitors), By Drug Class (Penicillin, Cephalosporins, Fluoroquinolones), And Segment Forecasts, 2019 - 2026,Grand View Research, Inc, INFORMS, Stable URL: https://www.grandviewresearch.com/industry-analysis/antibiotic-market. 33. (2014), The global economic impact of anti-microbial resistance, KPMG LLP, INFORMS, Stable URL: https://home.kpmg/content/dam/kpmg/pdf/2014/12/amr-report-final.pd. 34. Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, Cornaglia G, Garau J, Gniadkowski M, Hayden MK, Kumarasamy K, Livermore DM, Maya JJ, Nordmann P, Patel JB, Paterson DL, Pitout J, Villegas MV, Wang H, Woodford N, Quinn JP, (2013), Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases, Lancet Infect Dis, Interfaces, Vol. 13, No.9, P. 96-785, INFORMS, Stable URL: https://www.ncbi.nlm.nih.gov/pubmed/23969216. 35. 馬靈,蕭樑基,(2015),超級細菌之一:carbapenem resistant Enterobacteriaceae (CRE)在臺灣,國家衛生研究院,感染症與疫苗研究所,第25卷第3期,P. 140-143,感染控制雜誌,網址:file:///C:/Users/USER/Downloads/pdf%20(8).pdf. 36. 經濟部,駐休士頓台北經濟文化辦事處經濟組,(2019),美國低收入家庭消費年成長6%,折扣零售商受益,台灣經貿網,網址:https://info.taiwantrade.com/biznews/美國低收入家庭消費年成長6-折扣零售商受益-1813910.html. 37. (2018), DRIVEN TO DELIVER INNOVATIVE TREATMENTS FOR PATIENTS WITH INFECTIOUS DISEASES, Zavante Acquisition, Nabriva, INFORMS, Stable URL: https://investors.nabriva.com/static-files/7799d367-8f7e-4921-a035-e09e4840496a. 38. Marta Gonzalez Sanz, Michael Millar, Simon Tiberi, The elephant in the room: could the unregulated marketing of generic faropenem sodium be contributing to penem overuse? , Viewing Resistance surveillance & epidemiology: Gram-negatives, INFORMS, Stable URL: https://www.escmid.org/escmid_publications/escmid_elibrary/material/?mid=45306. 39. Sumanth Gandra, Eili Y. Klein, Suraj Pant, Surbhi Malhotra-Kumar, Ramanan Laxminarayan, (2016), Faropenem Consumption is Increasing in India, Clinical Infectious Diseases, Interfaces 62(8), P. 1050-1052, INFORMS, Stable URL: https://doi.org/10.1093/cid/ciw055. 40. Fabian Schmidt,(2019),印度抗生素隨便買抗藥性問題嚴重,科技環境,德國之聲中文網,網址:https://p.dw.com/p/3K0c6. 41. Atsuko Tsutsui, Koji Yahara, Keigo Shibayama, (2018), Trends and patterns of national antimicrobial consumption in Japan from 2004 to 2016, Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Higashimurayama, Journal of Infection and Chemotherapy , Japan , Interfaces 24(2018), P. 414-421, INFORMS, Stable URL: https://www.jiac-j.com/article/S1341-321X(18)30008-4/fulltext?mobileUi=0. 42. Bilal Aslam, Wei Wang, Muhammad Imran Arshad, Mohsin Khurshid, Saima Muzammil, Muhammad Hidayat Rasool, Muhammad Atif Nisar, Ruman Farooq Alvi, Muhammad Aamir Aslam, Muhammad Usman Qamar, Muhammad Khalid Farooq Salamat, Zulqarnain Baloch, (2018), Antibiotic resistance: a rundown of a global crisis , Infect Drug Resist, Interfaces 11(2018), P. 1645-1658, INFORMS, Stable URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188119/. 43. (2018), Global Meropenem Market 2018 Future Market Growth, Industry Developement Status, Outlook and Forecast till 2023,INFORMS, Stable URL: https://markettalknews.com/global-meropenem-market-status-outlook-research-2018-2023-by-key-players-applications-and-types/. 44. (2019),泰寧注射劑退出台灣?藥廠:持續供貨,三立新聞網,網址:https://www.setn.com/News.aspx?NewsID=514888. 45. 趙舒,(2016),培南類藥物異軍突起5大品種市場格局分析,醫藥經濟報,網址: https://med.sina.com/article_detail_103_1_606.html. 46. 南美洲聯盟 NASUL官網,網址:http://isags-unasur.org/a-estrutura-institucional-da-promocao-do-uso-racional-de-medicamentos-no-brasil/. 47. Curcio DJ, (2011), On behaf of the Latin American antibiotic use in intensive care unit group, Antibiotic prescription in intensive care units in Latin America, Rev Argent Microbiol, Interfaces 43(3), P. 11-203, INFORMS, Stable URL: https://www.ncbi.nlm.nih.gov/pubmed/22430995. 48. (2017), ANTIBACTERIAL AGENTS IN CLINICAL DEVELOPMENT, An analysis of the antibacterial clinical development pipeline, including tuberculosis, Department of Essential Medicines and Health Products, WHO, Switzerland, INFORMS, Stable URL: http://www.who.int/medicines/en/. 49. (2014),培南產品之比較,展旺生命科技法人說明會。 50. (2018), IMS (Intercontinental Marketing Services) Health. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/7984 | - |
dc.description.abstract | 本研究以抗生素的最後一道防線”碳青黴烯類(Cabapenems)”為主,來探討細菌治療多重抗性的發展,用以評估抗生素全球市場。由於Carbapenems抗生素,是屬於嚴重感染症的後線用藥,探討目的是要分析抗生素後線用藥在抗藥性日趨嚴重下,對抗生素市場是否有相關變化。
依IMS 數據分析目前上市之Carbapenems抗生素做2017年與2018年全球銷售額、消耗量統計及成長率分析,包含:美洛培南(Meropenem )、亞胺培南/西司他丁(Imipenem/Cilastatin )、厄它培南(Ertapenem)、多利培南(Doripenem)、法羅培南(Faropenem)、替比培南(Tebipenem)及比阿培南(Biapenem)等七種。其中未包含複方的帕尼培南/倍他米隆(Panipenem/ Betamipron),由於市場長期低迷,將不進行討論。整體而言,若以2017~2018年Carbapenems抗生素全球消耗量不分區域來看,總體消耗量下降6.7%,顯示全球已開發國家都已建立控管機制,已具有些許成效。 再以Carbapenems中市佔率第一的Meropenem來進行全球2015~2018年各區域的銷售額vs.消耗量相關性分析,藉以了解全球各區域市場銷售額與消耗量之相關性與差異。分析後發現,Carbapenems銷售額與消耗量之關係,取決於政府對藥價的定價方式,以美國及拉丁美洲來看,則無法從市場(銷售額)看出抗生素使用量關係,而歐洲、全球其他國家及台灣則呈現市場(銷售額)與抗生素使用量趨勢高度相關的結果。 台灣由2017年抗生素抗藥性監管成效來看,2008~2017年除了MRSA趨勢下降外,其他感染菌種皆持續上升中,與台灣Carbapenems抗生素消耗連續3年呈現大幅上升趨勢情況一致,顯見台灣抗生素抗藥性問題日趨嚴重。 如何抵抗超級細菌的威脅,是全球的重要課題,需要各國政府的積極政策推動。“推動的首要關鍵是,在患者剛剛輕微感染的第一個跡象下,獲得處方的權利將是全球抵抗抗藥性的推動者”。因此,需要更積極的開發國際運動與呼籲來教育醫療保健提供者,患者和非專業人員,以限制人類、農業及畜牧業中抗生素的過度使用和濫用。 | zh_TW |
dc.description.abstract | In this study, the last line of antibiotics, 'Cabapenems', was used to explore the development of multi-resistance in bacterial treatment to assess the global market for antibiotics. Because Carbapenems antibiotics are a late-line medication for serious infections, the purpose of the study is to analyze whether there is a relevant change in the antibiotic market under the increasing drug resistance of antibiotics. According to IMS data, the current markets Carbapenems antibiotics will be analyzed for global sales and consumption in 2017 and 2018, and growth rates from 2017 to 2018, including seven species: Meropenem, Imipenem/Cilastatin, Ertapenem, Doripenem, Faropenem, Tebipenem, and Biapenem. Panipenem/Betamipron, which does not contain the compound, will not be discussed due to the long-term downturn in the market. Overall, if the global consumption of Carbapenems antibiotics is not divided into regions in 2017~2018, the overall consumption was decreased by 6.7%, indicating that the developed countries have established control antibiotic resistance and have some success results. Based on Meropenem, the market share of Carbapenems, the correlation analysis of sales and consumption in various regions in the global from 2015 to 2018 was conducted to understand the correlation between the market and antibiotic resistance. After analysis, it is found that the relationship between sales and consumption of Carbapenems depends on the government's pricing method for drug prices. In the United States and Latin America, the relationship between antibiotic usage cannot be seen from the market (sales), while Europe and the world other countries and Taiwan have shown a high correlation between market (sales) and antibiotic using trends. Taiwan's 2017 antibiotic resistance surveillance control effect, in addition to the decline in MRSA trends in 2008~2017, other infectious strains continue to rise, consistent with the situation that Taiwan's Carbapenems antibiotic consumption has shown a sharp upward trend for three consecutive years. It is obvious that the problem of antibiotic resistance in Taiwan is becoming more and more serious.
How to resist the threat of super bacteria is an important issue in the global and requires the active policy promotion of governments. “The first key to the push is that under the first trace of a patient's initial mild infection, the right to get a prescription will be the promoter for Global resistance to drug resistance.”Therefore, there is a need for more active development of international campaigns and appeals to educate health care providers, patients and non-professionals to limit the excessive use and abuse of antibiotics in human, agricultural and livestock industries. | en |
dc.description.provenance | Made available in DSpace on 2021-05-19T18:01:27Z (GMT). No. of bitstreams: 1 ntu-108-P06e43023-1.pdf: 4859220 bytes, checksum: 011c3c67672fc8e193d5deedfb1d7316 (MD5) Previous issue date: 2019 | en |
dc.description.tableofcontents | 目錄
口試委員會審定書 i 誌謝 ii 中文摘要 iii ABSTRACT iv 目錄 v 圖目錄 vii 表目錄 x 第一章 緒論 1 第一節. 研究動機 1 第二節. 抗生素歷史 1 第三節. 抗生素分類 3 第四節. 抗生素的濫用及抗藥性 5 第五節. 研究目的 7 第六節. 研究流程與結構 8 第二章 相關文獻與研究 8 第一節. 研究材料與方法 8 第二節. 全球推動抗生素抗藥性行動 9 第三節. 全球抗生素使用報告 15 第四節. 各國抗生素監管成效 20 第五節. 台灣抗生素抗藥性總體環境(PEST)分析 25 第三章 製藥業概況 27 第一節. 全球藥品市場現況及未來趨勢 27 第二節. 全球學名藥與原料藥市場 34 第三節. 全球抗生素市場與五力分析 36 第四節. 台灣抗生素市場與SWOT分析 38 第四章 個案分析 39 第一節. Carbapenems抗生素產品種類 39 第二節. Carbapenems抗生素抗藥性發展 44 第三節. Carbapenems全球市場概況 48 第四節. Carbapenems產品概況 58 第五節. 市場銷售額與消耗量分析 67 第六節. Carbapenems台灣趨勢 71 第五章 結論與未來展望 73 第一節. 結論 73 第二節. 未來展望 77 參考文獻 78 | |
dc.language.iso | zh-TW | |
dc.title | 以碳青黴烯類的細菌治療多重抗性來評估抗生素的全球市場 | zh_TW |
dc.title | Evaluating the global antibiotic market from a unique presepective of multidrug resistant bacterial infection with a focus on the carbapenems | en |
dc.type | Thesis | |
dc.date.schoolyear | 107-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 何佳安(J.-a. Ho),孔令傑(Ling-Chieh Kung) | |
dc.subject.keyword | 抗生素抗藥性,抗生素市場,碳青黴烯類,培南類抗生素,美洛培南,亞胺培南/西司他丁,厄它培南, | zh_TW |
dc.subject.keyword | antibiotic resistance,antibiotic market,carbapenems,peinan antibiotics,Meropenem,Imipenem/Cilastatin,Ertapenem, | en |
dc.relation.page | 81 | |
dc.identifier.doi | 10.6342/NTU201903938 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2019-08-18 | |
dc.contributor.author-college | 進修推廣學院 | zh_TW |
dc.contributor.author-dept | 生物科技管理碩士在職學位學程 | zh_TW |
顯示於系所單位: | 生物科技管理碩士在職學位學程 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-1.pdf | 4.75 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。